Discordance of apolipoprotein B with low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol and coronary atherosclerosis

被引:19
|
作者
Su, Xin [1 ,2 ]
Cai, Xueli [3 ]
Pan, Yuesong [4 ,5 ]
Sun, Jingping [3 ]
Jing, Jing [4 ,5 ]
Wang, Mengxing [4 ,5 ]
Meng, Xia [4 ,5 ]
Wang, Yongjun [4 ,5 ]
Wei, Tiemin [6 ]
He, Yan [1 ,2 ]
机构
[1] Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China
[2] Beijing Municipal Key Lab Clin Epidemiol, Beijing, Peoples R China
[3] Zhejiang Univ, Lishui Hosp, Dept Neurol, Sch Med, Lishui, Peoples R China
[4] Capital Med Univ, Dept Neurol, Beijing Tiantan Hosp, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[6] Zhejiang Univ, Lishui Hosp, Dept Cardiol, Sch Med, Lishui, Peoples R China
基金
中国国家自然科学基金;
关键词
Apolipoproteins; Coronary atherosclerosis plaques; Discordance analysis; Lipoproteins; PROGNOSTIC VALUE; LDL-CHOLESTEROL; ARTERY CALCIFICATION; COMPUTED-TOMOGRAPHY; RISK; ANGIOGRAPHY; DISEASE; EVENTS; DYSLIPIDEMIA; MANAGEMENT;
D O I
10.1093/eurjpc/zwac223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims High level of apolipoprotein B (Apo B) is associated with incident subclinical atherosclerosis. The present study evaluated the associations between discordant Apo B with low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and coronary atherosclerotic burden. Methods and results This study enrolled 3043 participants aged 50-75 years from the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE) study that was conducted in the community in Lishui City, China. Discordant Apo B with LDL-C and non-HDL-C were defined by residuals and medians. Coronary atherosclerotic burden was evaluated by segment involvement score (SIS) and segment stenosis score (SSS) which were determined by computed tomography angiography. We performed discordance analyses examining associations of discordant Apo B with LDL-C or non-HDL-C with the coronary atherosclerotic burden. The mean age of participants was 61.2 +/- 6.7 years, 53.6% were females. Participants with discordant high Apo B relative to non-HDL-C were at higher odds of plaques [odds ratio (OR), 1.30; 95% confidence interval (CI), 1.08-1.57], SIS [common odds ratio (cOR), 1.35; 95% CI, 1.14-1.60], and SSS (cOR, 1.40; 95% CI, 1.18-1.67) compared with concordant group. However, discordantly low Apo B with non-HDL-C was associated with decreased odds of the coronary atherosclerotic plaques and its burden. Similar results were shown for discordant analyses for Apo B with LDL-C. Conclusion Discordantly high Apo B with LDL-C and non-HDL-C were associated with an increased odds of the coronary atherosclerotic plaques and its burden. These findings highlighted the importance of Apo B for primary prevention of coronary atherosclerosis.
引用
收藏
页码:2349 / 2358
页数:10
相关论文
共 50 条
  • [41] Correlation of Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin plus Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)
    Grundy, Scott M.
    Vega, Gloria Lena
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (04): : 548 - 553
  • [42] Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
    Grundy, SM
    CIRCULATION, 2002, 106 (20) : 2526 - 2529
  • [43] Apolipoprotein B versus non-high-density lipoprotein cholesterol: is the debate really over?
    Bittner, Vera
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (18) : 2372 - 2373
  • [44] Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
    Feeman, WE
    CIRCULATION, 2003, 107 (20) : E199 - E199
  • [45] Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: MERCURY II trial
    Ballantyne, Christie M.
    Raichlen, Joel S.
    Cain, Valerie A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E59 - E59
  • [46] Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Progression of Coronary Artery Calcification in Middle Age
    Kim, Chan-Won
    Hong, Sungwoo
    Chang, Yoosoo
    Lee, Jung Ah
    Shin, Hocheol
    Ryu, Seungho
    CIRCULATION JOURNAL, 2021, 85 (06) : 900 - +
  • [47] Relationship between non-high-density lipoprotein cholesterol/apolipoprotein A-I and monocyte/high-density lipoprotein cholesterol ratio and coronary heart disease
    Li, Ya
    Li, Shu
    Ma, Yulin
    Li, Jialing
    Lin, Mingying
    Wan, Jing
    CORONARY ARTERY DISEASE, 2020, 31 (07) : 623 - 627
  • [48] Apolipoprotein B, Low-Density Lipoprotein Particle Number, Non-High-Denisity Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Total Cholesterol for Atherosclerotic Cardiovascular Disease Risk Prediction in Young Adults
    Wilkins, John T.
    Ning, Hongyan
    Sawicki, Konrad
    Sawicki, Konrad T.
    Sniderman, Allan D.
    Otvos, James D.
    Rana, Jamal S.
    Murthy, Venkatesh
    Murthy, Venkatesh L.
    Shah, Ravi V.
    Allen, Norrina B.
    Lloyd-Jones, Donald
    CIRCULATION, 2023, 147
  • [49] The Utility of Non-High-Density Lipoprotein Cholesterol Levels Compared to Low-Density Lipoprotein Levels for Targets in Diabetes Individuals
    Woo, Vincent
    Stephenson, Hannah
    DIABETES, 2014, 63 : A568 - A569
  • [50] Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study
    Okamura, Tomonori
    Kokubo, Yoshihiro
    Watanabe, Makoto
    Higashiyama, Aya
    Miyamoto, Yoshihiro
    Yoshimasa, Yasunao
    Okayama, Akira
    ATHEROSCLEROSIS, 2009, 203 (02) : 587 - 592